Stay updated on Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial page.

Latest updates to the Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial page
- Check5 days agoChange DetectedThe revision label at the bottom of the page updated from v3.5.4 to v3.5.5, signaling a new platform revision was deployed. This change does not modify study data, text, or core functionality visible to users.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedA new revision entry v3.5.4 was added to the record history, and the previous revision entry v3.5.3 was removed, indicating an update to the study record's versioning in the history view.SummaryDifference0.1%

- Check48 days agoChange DetectedThe page’s interface revision label was updated from **v3.5.0** to **v3.5.3**, indicating a minor software/version change rather than a change to the clinical trial record itself.SummaryDifference0.1%

- Check84 days agoChange DetectedFooter revision label updated to v3.5.0, replacing the previous v3.4.3.SummaryDifference0.1%

- Check98 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3 in the page history.SummaryDifference0.1%

- Check120 days agoChange DetectedA new revision v3.4.2 was added to the history, replacing the previous v3.4.1.SummaryDifference0.1%

Stay in the know with updates to Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial page.